Penumbra Inc
$ 314.89
-0.66%
29 Dec - close price
- Market Cap 12,331,778,000 USD
- Current Price $ 314.89
- High / Low $ 319.78 / 312.91
- Stock P/E 75.15
- Book Value 34.70
- EPS 4.19
- Next Earning Report 2026-02-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.13 %
- 52 Week High 321.38
- 52 Week Low 221.26
About
Penumbra, Inc. is a leading biotechnology-driven medical device company headquartered in Alameda, California, specializing in innovative solutions for neurological and vascular conditions. With a growing global presence across the United States, Europe, Canada, and Australia, Penumbra is committed to advancing patient care through its state-of-the-art therapeutic products. The company’s relentless focus on quality and technological innovation positions it as a pivotal force in the rapidly evolving medical technology landscape, consistently enhancing both patient outcomes and clinician efficiency.
Analyst Target Price
$327.94
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-07-29 | 2025-05-05 | 2025-02-20 | 2024-10-30 | 2024-07-30 | 2024-05-07 | 2024-02-22 | 2023-11-02 | 2023-08-01 | 2023-05-02 | 2023-02-23 |
| Reported EPS | 0.97 | 0.86 | 0.83 | 0.97 | 0.85 | 0.64 | 0.41 | 0.76 | 0.67 | 0.43 | 0.23 | 0.16 |
| Estimated EPS | 0.9265 | 0.83 | 0.7547 | 0.8937 | 0.69 | 0.56 | 0.38 | 0.7 | 0.45 | 0.28 | 0.11 | 0.15 |
| Surprise | 0.0435 | 0.03 | 0.0753 | 0.0763 | 0.16 | 0.08 | 0.03 | 0.06 | 0.22 | 0.15 | 0.12 | 0.01 |
| Surprise Percentage | 4.6951% | 3.6145% | 9.9775% | 8.5375% | 23.1884% | 14.2857% | 7.8947% | 8.5714% | 48.8889% | 53.5714% | 109.0909% | 6.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PEN
2025-12-29 21:09:18
Penumbra, Inc. announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 6:45 PM ET. A webcast of the presentation will be available on the company's website under the "Investors" tab. Penumbra is a leading thrombectomy company focused on innovative technologies for challenging medical conditions such as ischemic stroke and pulmonary embolism.
2025-12-24 08:09:16
A new study published in the American Journal of Cardiology indicates that Computer Assisted Vacuum Thrombectomy (CAVT) for intermediate-risk pulmonary embolism (PE) can significantly shorten hospital stays, reduce complications, and improve discharge outcomes without increasing mortality. The research highlights CAVT's potential to lower healthcare costs by decreasing resource utilization compared to other treatment modalities. Patients treated with CAVT experienced shorter lengths of stay and fewer complications, leading to a higher likelihood of discharge to home.
2025-12-23 08:09:42
Penumbra Inc. (PEN) experienced a significant milestone, with its stock reaching a 52-week high of $320.12, reflecting a 33.03% increase over the past year and outperforming with a 30.25% total return. Despite technical indicators suggesting potential overbought territory and trading above its Fair Value, the company has demonstrated solid revenue growth and a strong buy consensus recommendation from analysts. Recent strong third-quarter financial results led to raised revenue guidance and positive analyst responses, with upgrades and increased price targets.
2025-12-22 18:08:46
Penumbra Inc. (PEN) stock reached a 52-week high of $320.12, marking a 33.03% increase over the past year. The company's strong performance is supported by robust revenue growth and a "strong buy" consensus from analysts, though technical indicators suggest it may be overbought and trading above its Fair Value. Recent positive Q3 financial results and raised revenue guidance for 2025 have further fueled investor confidence, leading to several analyst upgrades and increased price targets.
2025-12-21 09:09:34
Congress Asset Management Co. recently reduced its stake in Penumbra, Inc. (NYSE:PEN) by 5.6%, now holding 429,172 shares valued at $108.72 million. Despite this reduction, analyst sentiment remains largely bullish, with several firms upgrading ratings and raising price targets following Penumbra's strong quarterly earnings report that surpassed expectations. Insiders have also sold shares, but institutional ownership stands at 88.88%.
2025-12-18 16:09:47
Truist Financial raised its price target for Penumbra (NYSE:PEN) to $370 from $312, maintaining a "buy" rating, indicating an 18.11% upside. This positive outlook is echoed by other firms, with a consensus "Moderate Buy" rating and an average target of $333.47. Penumbra's fundamentals remain strong, with exceeded quarterly earnings expectations and 17.8% year-over-year revenue growth, despite recent insider share sales.
